Researchers at the University of Dundee and University College London on Wednesday reported that taking the maximum daily dose of some medicines would exceed the recommended daily limits for sodium, without any additional dietary intake, and potentially become an added risk factor for heart disease.
The Food and Drug Administration today approved Adempas, also known as riociguat, to treat adults with two forms of pulmonary hypertension, which is caused by abnormally high blood pressure in the arteries of the lungs.
In collaboration with Walgreens, the University of Nebraska Medical Center unveiled a new treatment model to help positively impact clinical outcomes for hypertension and Type 2 diabetes patients through a program made possible by a National Association of Chain Drug Stores Foundation grant.
PharmaSmart International’s comprehensive blood pressure program has recently been validated in two new, independent scientific studies, the company announced today. The company also announced a partnership with Rx-30 Pharmacy System that offers an automated clinical integration of validated PharmaSmart biometrics within the patient record.